Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ocrelizumab - Biogen/Genentech

Drug Profile

Ocrelizumab - Biogen/Genentech

Alternative Names: 2H7-monoclonal-antibody; 2nd Generation Anti-CD20; Anti-CD20 monoclonal antibody - Genentech; Humanised Anti-CD20 mAb; Monoclonal-antibody-2H7; OCR; OCRE; Ocrevus; Ocrevus SC; PRO 70769; R 1594; RG 1594; rhuMab 2H7; RO4964913

Latest Information Update: 15 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biogen Idec; Genentech
  • Developer Biogen; Biogen Idec; Chugai Pharmaceutical; Genentech; Roche
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies; Urologics
  • Mechanism of Action Antibody-dependent cell cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis
  • Discontinued Eye disorders; Haematological malignancies; Lupus nephritis; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 02 Apr 2025 Adverse events and efficacy data from a phase-III MUSETTE trial in Multiple sclerosis released by Roche
  • 27 Feb 2025 Efficacy and adverse event data from a phase III trial for Multiple Sclerosis presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum (ACTRIMS-2025)
  • 27 Feb 2025 Updated adverse events and efficacy data from the phase-III OCARINA II trial in Multiple sclerosis presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum (ACTRIMS-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top